1887
Volume 2025, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by excessive immune activation. Children with Down syndrome (DS) (trisomy 21) are at increased risk of severe infections and immune dysregulation. Although viral infections are known triggers of secondary HLH, H1N1 influenza is an uncommon cause in this population.

We report a 1.8-month-old male infant with DS and multiple comorbidities—including gastroesophageal reflux disease (GERD), recurrent aspiration pneumonia, and seizures—who presented with fever, hypoxemia, and splenomegaly. Laboratory investigations revealed cytopenias, hyperferritinemia (>1,650 ng/mL), and hypofibrinogenemia, fulfilling five of the HLH-2004 diagnostic criteria. H1N1 influenza was confirmed as the infectious trigger. The patient was treated with standard-dose dexamethasone and etoposide, along with oseltamivir. Despite concerns about treatment-related toxicity in DS, he tolerated the regimen without hematologic or infectious complications. He achieved clinical remission with normalization of inflammatory markers and hematologic parameters. At discharge and at three-month follow-up, he remained well with no recurrence or neurological sequelae.

This case highlights the diagnostic and therapeutic challenges of managing HLH in children with DS. The use of conventional HLH therapy, including etoposide, was effective and well-tolerated despite theoretical concerns in this population. Although central nervous system symptoms were present, they resolved with treatment. H1N1 influenza should be considered a potential viral trigger in immunocompromised children presenting with HLH-like features.

H1N1 influenza-induced HLH is exceptionally rare in infants with DS. The positive outcome in this case supports the safe use of standard HLH protocols in this vulnerable population and highlights the importance of early diagnosis and multidisciplinary management to optimize outcomes.

© 2025 Khoursheed, Dawoud, Qandeel, Qteishat, Sweedan, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.120
2025-12-14
2025-12-14

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/4/qmj.2025.120.html?itemId=/content/journals/10.5339/qmj.2025.120&mimeType=html&fmt=ahah

References

  1. Bull MJ. Down syndrome. N Engl J Med. 2020; 382:(24):2344–52. https://doi.org/10.1056/NEJMra1706537
     [Google Scholar]
  2. Kusters MA, Verstegen RH., Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: A review. Clin Exp Immunol. 2009; 156:(2):189–93. https://doi.org/10.1111/j.1365-2249.2009.03890.x
     [Google Scholar]
  3. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007; 21:(5):245–53. https://doi.org/10.1016/j.blre.2007.05.001
     [Google Scholar]
  4. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014; 383:(9927):1503–16. https://doi.org/10.1016/S0140-6736(13)61048-X
     [Google Scholar]
  5. Hainsworth JD, Greco FA. Etoposide: Twenty years later. Ann Oncol. 1995; 6:(4):325–41. https://doi.org/10.1093/oxfordjournals.annonc.a059180
     [Google Scholar]
  6. Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A, et al. Hemophagocytic lymphohistiocytosis: Current treatment advances, emerging targeted therapy and underlying mechanisms. J Hematol Oncol. 2024; 17:106. https://doi.org/10.1186/s13045-024-01621-x
     [Google Scholar]
  7. George MR. Hemophagocytic lymphohistiocytosis: Review of etiologies and management. J Blood Med. 2014 Jun 12; 5:69–86. https://doi.org/10.2147/JBM.S46255
     [Google Scholar]
  8. Hameed M, Garcia G, Zhen KC, Hartenstein B, Herrera LDJ, Hamad K, et al. Secondary hemophagocytic lymphohistiocytosis (HLH): A systematic review of incidence and prognostic outcomes. Blood. 2024; 144: (Supplement 1):5374. https://doi.org/10.1182/blood-2024-202645
     [Google Scholar]
  9. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015; 2015:177–82. https://doi.org/10.1182/asheducation-2015.1.177
     [Google Scholar]
  10. Lai S, Merritt BY, Chen L, Zhou X, Green LK. Hemophagocytic lymphohistiocytosis associated with influenza A (H1N1) infection in a patient with chronic lymphocytic leukemia: An autopsy case report and review of the literature. Ann Diagn Pathol. 2012; 16:(6):477–84. https://doi.org/10.1016/j.anndiagpath.2011.03.009
     [Google Scholar]
  11. Jilani TN, Jamil RT, Nguyen AD, Siddiqui AH. H1N1 influenza. StatPearls. Treasure Island FL: StatPearls Publishing; 2025.
     [Google Scholar]
  12. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011; 164:(1): 9–16. https://doi.org/10.1111/j.1365-2249.2011.04335.x
     [Google Scholar]
  13. Horne A, Wickström R, Jordan MB, Yeh EA, Naqvi A, Henter JI, et al. How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr Treat Options Neurol. 2017; 19:(1):3. https://doi.org/10.1007/s11940-017-0439-4
     [Google Scholar]
  14. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020; 135:(16):1332–43. https://doi.org/10.1182/blood.2019000936
     [Google Scholar]
  15. Kim H, Mizuno K, Masuda K, Sakurai M, Ara T, Naito K, et al. A nationwide retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult hemophagocytic lymphohistiocytosis. Transplant Cell Ther. 2024; 30:(4):419.e1–12. https://doi.org/10.1016/j.jtct.2024.01.071
     [Google Scholar]
  16. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48:(2):124–31. https://doi.org/10.1002/pbc.21039
     [Google Scholar]
  17. Lazea C, Blag C. Hemophagocytic lymphohistiocytosis secondary to Mycoplasma pneumoniae infection in a trisomy 21 girl. Rev Rom Med Lab. 2018; 26:(1):113–7. https://doi.org/10.1515/rrlm-2017-0039
     [Google Scholar]
  18. Kim-Hellmuth S, Hermann M, Eilenberger J, Ley-Zaporozhan J, Fischer M, Hauck F. et al. SARS-CoV-2 triggering severe acute respiratory distress syndrome and secondary hemophagocytic lymphohistiocytosis in a 3-year-old child with Down syndrome. J Pediatric Infect Dis Soc. 2021 Apr 30; 10:(4):543–6. https://doi.org/10.1093/jpids/piaa148
     [Google Scholar]
  19. Dupont T, Darmon M, Mariotte E, Lemiale V, Fadlallah J, Mirouse A, et al. Etoposide treatment in secondary hemophagocytic syndrome: Impact on healthcare-associated infections and survival. Ann Intensive Care. 2022; 12:(1):101. https://doi.org/10.1186/s13613-022-01075-9
     [Google Scholar]
  20. Agress A, Malle L, Eisenberg R, Bogunovic D. Five interferon receptor triplicates: A unique case of hemophagocytic lymphohistiocytosis in a Down syndrome patient. Ann Allergy Asthma Immunol. 2022; 129:(5):S128. https://doi.org/10.1016/j.anai.2022.08.872
     [Google Scholar]
  21. Guild A, Fritch J, Patel S, Reinhardt A, Acquazzino M. Hemophagocytic lymphohistocytosis in trisomy 21: Successful treatment with interferon inhibition. Pediatr Rheumatol Online J. 2022 Nov 18; 20:(1):104. https://doi.org/10.1186/s12969-022-00764-w
     [Google Scholar]
/content/journals/10.5339/qmj.2025.120
Loading
H1N1-associated hemophagocytic lymphohistiocytosis in a child with Down syndrome: A clinical challenge
Qatar Medical Journal 2025, 120 (2025); https://doi.org/10.5339/qmj.2025.120
/content/journals/10.5339/qmj.2025.120
/content/journals/10.5339/qmj.2025.120
Loading

Data & Media loading...

  • Article Type: Case Report
Keyword(s): Down syndrome, H1N1 influenza, Hemophagocytic lymphohistiocytosis, immunosuppression therapy and secondary HLH

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error